Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

No Cell Therapy-Related Updates in August’s CHMP Agenda

Here is a brief preview of this blast: On Tuesday, August 16, the CHMP agenda for August was released. As previously anticipated by the Celltelligence team, no cell therapy-related updates were observed. Recall that for the CHMP meetings from June and July 2022, the Celltelligence team prepared two full analyses providing the following EC approval timelines for Breyanzi (BMS’s CD19 CAR-T) and Yescarta (Gilead / Kite’s CD19 CAR-T):

About The Author

The Celltelligence Team

Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.